PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.
Unternehmens-codePAVMZ
Name des UnternehmensPAVmed Inc
IPO-datumJul 27, 2016
Gegründet am2014
CEODr. Lishan Aklog, M.D.
Anzahl der mitarbeiter39
WertpapierartCompany Warrant
GeschäftsjahresendeJul 27
Addresse360 Madison Avenue
StadtNEW YORK
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl10017
Telefon12129494319
Websitehttps://pavmed.com/
Unternehmens-codePAVMZ
IPO-datumJul 27, 2016
Gegründet am2014
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten